Instructions on the contraindications and unsuitable groups for the use of Giritinib (Segatan)

Gilitinib is an oral targeted drug targeting FLT3-mutated acute myeloid leukemia (AML), which has the effect of inhibiting tumor cell proliferation. Although the drug has clear efficacy, it is not suitable for all patients. Before treatment, doctors need to determine whether there are any contraindications or risks to medication based on the patient's health status, past medical history, and laboratory test results.

Patients who are allergic to giritinib or its components are absolutely contraindicated. If you have experienced reactions such as severe rash, difficulty breathing or anaphylactic shock, you should avoid using it again. In addition, it is not recommended for people with severe liver damage. Giritinib is mainly metabolized by the liver, and abnormal liver function may lead to accumulation of the drug, causing elevated transaminases or liver damage. For patients with mild to moderate liver dysfunction, medication can be used with caution under the guidance of a doctor, and liver function should be monitored regularly.

Patients with underlying cardiovascular diseases or arrhythmias need special attention. Geretinib may cause QT interval prolongation and arrhythmia, and concomitant use of other drugs that prolong the QT interval (such as some antibiotics or antiarrhythmic drugs) may increase the risk of cardiac events. Doctors usually require an electrocardiogram before prescribing medication and continue to monitor it during treatment. If obvious abnormalities are found, medication must be suspended.

Giritinib is not recommended for pregnant women, lactating women and minor patients. Animal experiments suggest that the drug may cause harm to the fetus, so women of childbearing age should take reliable contraceptive measures during treatment. Breastfeeding women should avoid taking medication or suspend breastfeeding to prevent the medication from affecting the baby through milk. Generally speaking, although giritinib is an important therapeutic drug for FLT3mutated AML, it must be strictly screened for contraindications when used, and electrocardiogram and liver function must be monitored as directed by the doctor to ensure a balance between drug safety and efficacy.

Reference materials:https://www.drugs.com/